474 – Optimized ACE2-Fc With Picomolar Pan-Neutralization of SARS-CoV-2 Variants, Including JN.1 and KP.2
Background Many neutralizing monoclonal antibodies capable of providing sterilizing immunity against SARS-CoV-2 have been developed and temporarily approved for emergency clinical use as prophylactics. However, the rapid evolution of SARS-CoV-2 progressively renders these treatments obsolete. Several groups have been exploring the use of ACE2-based Fc fusion proteins to obtain a pan-variant neutralizing molecule. In this…